Be Biopharma的封面图片
Be Biopharma

Be Biopharma

生物技术

Cambridge,Massachusetts 8,380 位关注者

Engineered B cells as medicines

关于我们

Be Bio is pioneering Engineered B Cell Medicines (BCMs) to dramatically improve the lives of patients who are living with Hemophilia B and other genetic diseases, cancer, and other serious conditions. With eyes locked on the patient, our team of purpose-driven scientists, technologists, manufacturing experts and business builders collaborate to create a bold new class of cell therapies.

网站
https://www.be.bio
所属行业
生物技术
规模
51-200 人
总部
Cambridge,Massachusetts
类型
私人持股
创立
2020

地点

  • 主要

    One Kendall Square

    Building 200, Floor 3

    US,Massachusetts,Cambridge,02139

    获取路线

Be Biopharma员工

动态

  • 查看Be Biopharma的组织主页

    8,380 位关注者

    Throughout history, women in science have broken barriers, advanced knowledge, and changed the course of medicine. Their courage, brilliance, and persistence continue to reshape what’s possible for patients. At Be Bio, we put our shoulders to the wheel alongside them. Our leadership team is powered by pioneering scientists, operators, and business builders—women (and men) whose fierce dedication to our mission inspires us to develop a new class of medicines and transform patient lives. This #WomensHistoryMonth, we celebrate the women whose work has paved the way—and those who are forging new paths today. Together, we push boundaries, challenge the impossible, and build the future of medicine in service of the countless patient stories we exist to change. #WomenInLeadership #BeBio

  • 查看Be Biopharma的组织主页

    8,380 位关注者

    Be Bio welcomes Susan Abu-Absi, Ph.D., as our new Chief Operating Officer! Dr. Abu-Absi brings 20+ years of operational and manufacturing experience in biologics and #CellAndGeneTherapy. “Susan is an outstanding leader and accomplished executive whose experience will further strengthen our leadership team as we solidify our position as a multi-program, clinical-stage company,” said Joanne Smith-Farrell, Ph.D., Chief Executive Officer. “She joins Be Bio at an ideal time, with enrollment now underway in the BeCoMe-9 trial for BE-101 in Hemophilia B, and with our development candidate, BE-102, progressing toward IND as a potential breakthrough for patients with Hypophosphatasia. We look forward to leveraging Susan’s expertise as we pioneer our B Cell Medicines to potentially transform the treatment landscape for a wide range of diseases.” Read the press release here: https://lnkd.in/eDCiZPQN

    • 该图片无替代文字
  • 查看Be Biopharma的组织主页

    8,380 位关注者

    At Be Bio, we recognize diversity as a catalyst for innovation, creativity, and growth. This Black History Month–and every day, we honor the contributions of Black leaders, innovators, and pioneers who have shaped healthcare. By championing diverse voices and perspectives, we remain committed to creating a future where healthcare is inclusive, equitable, and accessible for all. #BeBio #BlackHistoryMonth

    • 该图片无替代文字
  • 查看Be Biopharma的组织主页

    8,380 位关注者

    We’re excited to announce the publication of our manuscript in the journal Molecular Therapy titled, “In vivo tracking of ex vivo generated 89Zr-oxine labeled plasma cells by PET in a non-human primate model,” highlighting first-of-its-kind preclinical research from a collaboration study showing homing and engraftment of ex-vivo-generated plasma cells in non-human primates (NHPs) with intact immune systems. Read the manuscript here: https://lnkd.in/eQezBxh7

    • 该图片无替代文字
  • 查看Be Biopharma的组织主页

    8,380 位关注者

    Do you have expertise in cGMP, GCP, GLP, and global regulatory requirements? We’re looking for a Quality Assurance Senior Director to join our team. Take part in leading the development of our Quality Management Systems, driving compliance, and ensuring top standards in clinical and manufacturing operations. Join us in advancing innovative therapies for patients in need. Tap the link for additional details and application link: https://lnkd.in/ei9F4yxH

    • 该图片无替代文字

相似主页

查看职位

融资

Be Biopharma 共 4 轮

上一轮

C 轮

US$92,000,000.00

Crunchbase 上查看更多信息